It's almost impossible to map out study budgets with absolute precision. Planning for the unexpected costs, such as those associated with slow enrollment, protocol amendments, and other contingencies—is vital.
Irina Petrova
Advertisement
Articles by Irina Petrova
Applied Clinical Trials
Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, explores why U.S. companies are turning to Russa after having secured approval for 108 trials there in 2018.
Advertisement
Latest Updated Articles
- Why do U.S. Sponsors Come to Russia for Clinical Trials?
July 10th 2019
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny
2
Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It
3
How AI Is Changing Endpoint Selection Before a Trial Even Starts
4
How to recruit specialty volunteer populations for early-phase clinical research: 5 things to ask when choosing a CRO partner
5